Synapse - Dean Bajorin

Results (663)

Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC)

Meeting Abstract

Sonpavde, G.; Pond, G. R.; Rosenberg, J. E.; Bajorin, D. F.; Regazzi, A. M.; Mullane, S. A.; Niegisch, G.; Albers, P.; Necchi, A.; di Lorenzo, G.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance

Meeting Abstract

Lin, C. C.; Bruinooge, S. S.; Kirkwood, K. M.; Olsen, C. C.; Bajorin, D. F.; Jemal, A.; Giordano, S. H.; Goldstein, M.; Guadagnolo, B. A.; Kosty, M. P.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer

Meeting Abstract

Bellmunt, J.; Sonpavde, G.; De Wit, R.; Choueiri, T. K.; Siefker-Radtke, A. O.; Plimack, E. R.; Lewis, N. M.; Brown, H.; Mai, Y. B.; Gause, C. K.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma

Meeting Abstract

Bambury, R. M.; Jordan, E.; Zabor, E. C.; Bouvier, N.; Al-Ahmadie, H.; Boyd, M. E.; Mullane, S. A.; Cha, E. K.; Ostrovnaya, I.; Hyman, D. M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy

Meeting Abstract

Bajorin, D. F.; Plimack, E. R.; Siefker-Radtke, A. O.; Choueiri, T. K.; De Wit, R.; Sonpavde, G.; Gipson, A.; Brown, H.; Mai, Y. B.; Pang, L.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma

Meeting Abstract

Sonpavde, G.; Pond, G. R.; Rosenberg, J. E.; Bajorin, D. F.; Regazzi, A. M.; Choueiri, T. K.; Mullane, S. A.; Niegisch, G.; Albers, P.; Necchi, A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Comparison of genetic alterations from the bladder cancer genome atlas (TCGA) and a prospective set of high-grade urothelial carcinoma tumors using a CLIA laboratory next generation sequencing assay

Meeting Abstract

Iyer, G.; Bagrodia, A.; Cha, E. K.; Boyd, M. E.; Zehir, A.; Cheng, D. T.; Hyman, D. M.; Bambury, R. M.; Arcila, M. E.; Ladanyi, M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients

Meeting Abstract

Iyer, G.; Tully, C. M.; Garcia-Grossman, I. R.; Scott, S. N.; Boyd, M. E.; McCoy, A. S.; Berger, M. F.; Al-Ahmadie, H.; Solit, D. B.; Rosenberg, J. E.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Split-dose cisplatin as an alternative to every-3-week dosing when using cisplatin/gemcitabine to treat advanced urothelial

Meeting Abstract

Gonzalez, C. M.; Jordan, E.; Zabor, E. C.; Kania, B. E.; Regazzi, A. M.; Ostrovnaya, I.; Iyer, G.; Bajorin, D. F.; Bambury, R. M.; Rosenberg, J. E.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Clonality of bladder tumors following radical nephroureterectomy: Against the field defect hypothesis

Meeting Abstract

Cha, E. K.; Sfakianos, J.; Scott, S. N.; Murugan, P.; Iyer, G.; Bagrodia, A.; Shah, R.; Bajorin, D. F.; Rosenberg, J. E.; Berger, M. F.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save